JP5373405B2 - 選択的アンドロゲン受容体モジュレーター - Google Patents
選択的アンドロゲン受容体モジュレーター Download PDFInfo
- Publication number
- JP5373405B2 JP5373405B2 JP2008556805A JP2008556805A JP5373405B2 JP 5373405 B2 JP5373405 B2 JP 5373405B2 JP 2008556805 A JP2008556805 A JP 2008556805A JP 2008556805 A JP2008556805 A JP 2008556805A JP 5373405 B2 JP5373405 B2 JP 5373405B2
- Authority
- JP
- Japan
- Prior art keywords
- cyano
- hydroxy
- compounds
- fluorophenoxy
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- GBJNJFHFMGGUBN-UHFFFAOYSA-N COC(c(cc(cc1)N)c1C#N)=O Chemical compound COC(c(cc(cc1)N)c1C#N)=O GBJNJFHFMGGUBN-UHFFFAOYSA-N 0.000 description 1
- 0 C[C@](CBr)(C(Nc(cc1C(*)=O)ccc1C#N)=O)O Chemical compound C[C@](CBr)(C(Nc(cc1C(*)=O)ccc1C#N)=O)O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Description
2−シアノ−5−[(S)−3−(4−シアノ−3−フルオロフェノキシ)−2−ヒドロキシ−2−メチルプロピオニル−アミノ]安息香酸、
(S)−3−(4−シアノ−3−フルオロフェノキシ)−N−(4−シアノ−3−ヒドロキシメチルフェニル)−2−ヒドロキシ−2−メチルプロピオンアミド、および
(S)−3−(4−シアノ−3−フルオロフェノキシ)−N−(4−シアノ−3−ホルミルフェニル)−2−ヒドロキシ−2−メチルプロピオンアミド
が挙げられる。
2−シアノ−5−[(S)−3−(4−シアノ−3−フルオロフェノキシ)−2−ヒドロキシ−2−メチルプロピオニル−アミノ]安息香酸、
(S)−3−(4−シアノ−3−フルオロフェノキシ)−N−(4−シアノ−3−ヒドロキシメチルフェニル)−2−ヒドロキシ−2−メチルプロピオンアミド、および
(S)−3−(4−シアノ−3−フルオロフェノキシ)−N−(4−シアノ−3−ホルミルフェニル)−2−ヒドロキシ−2−メチルプロピオンアミド
が挙げられる。
Claims (4)
- (2S)−3−(4−シアノ−3−フルオロフェノキシ)−N−(4−シアノ−3−メチルフェニル)−2−ヒドロキシ−2−メチルプロピオンアミドである請求項1記載の化合物。
- 請求項1または2記載の化合物を薬学的に許容され得る担体とともに含む医薬組成物。
- 治療的に有効量の請求項1または2記載の化合物を含むアンドロゲン受容体依存性の症状の治療または予防用医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77841706P | 2006-03-03 | 2006-03-03 | |
US60/778,417 | 2006-03-03 | ||
PCT/FI2007/000055 WO2007099200A1 (en) | 2006-03-03 | 2007-03-02 | Selective androgen receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009528333A JP2009528333A (ja) | 2009-08-06 |
JP5373405B2 true JP5373405B2 (ja) | 2013-12-18 |
Family
ID=37994519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008556805A Expired - Fee Related JP5373405B2 (ja) | 2006-03-03 | 2007-03-02 | 選択的アンドロゲン受容体モジュレーター |
Country Status (10)
Country | Link |
---|---|
US (1) | US8501814B2 (ja) |
EP (1) | EP1991523B1 (ja) |
JP (1) | JP5373405B2 (ja) |
AU (1) | AU2007220419B2 (ja) |
CA (1) | CA2642598C (ja) |
NO (1) | NO341158B1 (ja) |
NZ (1) | NZ570533A (ja) |
RU (1) | RU2435756C2 (ja) |
WO (1) | WO2007099200A1 (ja) |
ZA (1) | ZA200807551B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
BRPI0907844B8 (pt) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
WO2010002075A1 (en) * | 2008-07-02 | 2010-01-07 | Pharmacostech Co., Ltd. | Methods for preparing amide derivatives |
AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
US20130053448A1 (en) | 2010-05-12 | 2013-02-28 | Louis O'Dea | Therapeutic Regimens |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
FI20105806A0 (fi) * | 2010-07-15 | 2010-07-15 | Medeia Therapeutics Ltd | Uudet aryyliamidijohdannaiset, joilla on antiandrogeenisia ominaisuuksia |
US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
SI3122426T1 (sl) | 2014-03-28 | 2023-04-28 | Duke University | Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
WO2017223115A1 (en) | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
JP7473486B2 (ja) | 2018-07-04 | 2024-04-23 | ラジウス ファーマシューティカルズ,インコーポレイテッド | Rad1901-2hclの多形形態 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU88769I2 (fr) * | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
-
2007
- 2007-03-02 AU AU2007220419A patent/AU2007220419B2/en not_active Ceased
- 2007-03-02 NZ NZ570533A patent/NZ570533A/en not_active IP Right Cessation
- 2007-03-02 WO PCT/FI2007/000055 patent/WO2007099200A1/en active Application Filing
- 2007-03-02 JP JP2008556805A patent/JP5373405B2/ja not_active Expired - Fee Related
- 2007-03-02 US US12/280,026 patent/US8501814B2/en not_active Expired - Fee Related
- 2007-03-02 RU RU2008139315/04A patent/RU2435756C2/ru not_active IP Right Cessation
- 2007-03-02 CA CA2642598A patent/CA2642598C/en not_active Expired - Fee Related
- 2007-03-02 EP EP07712597A patent/EP1991523B1/en active Active
-
2008
- 2008-09-02 ZA ZA200807551A patent/ZA200807551B/xx unknown
- 2008-09-26 NO NO20084114A patent/NO341158B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1991523B1 (en) | 2012-08-15 |
AU2007220419A1 (en) | 2007-09-07 |
NZ570533A (en) | 2011-02-25 |
CA2642598A1 (en) | 2007-09-07 |
WO2007099200A1 (en) | 2007-09-07 |
RU2008139315A (ru) | 2010-04-10 |
RU2435756C2 (ru) | 2011-12-10 |
EP1991523A1 (en) | 2008-11-19 |
NO341158B1 (no) | 2017-09-04 |
CA2642598C (en) | 2014-05-27 |
ZA200807551B (en) | 2009-06-24 |
US8501814B2 (en) | 2013-08-06 |
AU2007220419B2 (en) | 2012-03-15 |
JP2009528333A (ja) | 2009-08-06 |
US20090054525A1 (en) | 2009-02-26 |
NO20084114L (no) | 2008-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5373405B2 (ja) | 選択的アンドロゲン受容体モジュレーター | |
JP5599380B2 (ja) | 選択的アンドロゲン受容体調節因子の固体形態 | |
CA2710205C (en) | An improved process to prepare treprostinil, the active ingredient in remodulin | |
JP2005508948A (ja) | 選択性の優れたシクロオキシゲナーゼ−2の阻害剤としての1h−インドール誘導体 | |
CN102702067B (zh) | 用于合成西洛多辛的中间体及其制备方法和用途 | |
JP2009526006A (ja) | トリアルキルシリルベンジルアミノカルボキシインドール、インダゾールおよびインドリン、ならびにcetpを介する障害の処置におけるそれらの使用 | |
CN1984878B (zh) | 用于治疗神经变性疾病的1-苯基烷羧酸的衍生物 | |
ES2536552T3 (es) | Proceso para la preparación de 2-amino-2-[2-(4-alquil-C3-C21-fenil)etil]propano-1,3-dioles | |
BE1003848A3 (fr) | Nouveaux derives de la thiouree, leur preparation et leur utilisation comme medicaments. | |
EP0343050B1 (fr) | Dérivés de phényl-6 pipérazinyl-alkyl-3 1H,3H-pyrimidinedione-2,4, leur préparation et leur application en thérapeutique | |
JP6148351B2 (ja) | 置換ピロリジン−2−カルボキサミドの不斉合成 | |
JP2022539126A (ja) | ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用 | |
CN1514825A (zh) | 可用于反流病的新化合物 | |
EP2066677B1 (en) | Pyridooxazepine progesteron receptor modulators | |
JP2014139175A (ja) | 治療化合物 | |
CA2548316A1 (en) | Preparation of r-5-(2-(2-ethoxyphenoxyetylamino)propyl)-2-methoxybenzenesulphonamide hydrochloride of high chemical | |
TWI268919B (en) | Ethers of O-desmethyl venlafaxine | |
CA1076117A (fr) | Procede d'obtention de nouveaux ethers aryliques et les produits en resultant | |
WO2008157271A1 (en) | Deuterium-enriched escitalopram | |
CN1138753C (zh) | 二甲基取代的环己二烯衍生物 | |
EP0514267B1 (fr) | Nouveaux dérivés amidiques de 1-amino octahydropyrido (2,1-c) (1,4) oxazine, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
BE863313A (fr) | M-sulfonamidobenzamides | |
JP2006225301A (ja) | オキソエステル化合物の製造方法 | |
RU2015964C1 (ru) | Способ получения замещенных производных амина | |
JPH03106867A (ja) | 1,3―オキサジン―4―オン化合物およびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100106 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100527 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120703 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130611 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130826 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130917 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130919 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |